Climb Bio's pMN Drug Shows B-Cell Depletion, Remission at 12 Weeks in Early Phase 2
CLYM has more than doubled off its 52-week low of $1.635 on light trading volume (0.4× avg).
Summary
Climb Bio's budoprutug produced B-cell depletion, PLA2R antibody reductions and immunologic remission at 12 weeks in the 200 mg arm of an early Phase 2 study in primary membranous nephropathy. The 600 mg cohort showed greater exposure and deeper depletion, a dose response that points to potentially stronger efficacy at higher doses. Both doses were generally well tolerated through Week 12 and Week 6 respectively, so escalation and enrollment can continue. This is a preliminary biomarker and safety readout, not a proteinuria or sustained-response result — the kind of data that de-risks the program but does not yet prove it works. It builds on the Phase 1 work the company and Mabworks presented at ASN Kidney Week on October 23, and comes with a $239.2 million cash balance that funds operations into the second half of 2028. The real test is longer follow-up and higher-dose cohort outcomes expected in 2027.
At the time of this announcement, CLYM was trading at $10.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $585.3M. The 52-week trading range was $1.64 to $18.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.